HIV test kit evaluations
Laboratory diagnosis of HIV infection generally focuses on detection of antibody to HIV. However, the new generation assays also incorporate HIV antigen detection to increase the sensitivity of the assay. In this way, a HIV antigen-antibody combination assay is helpful in closing the window period (the time between HIV infection and appearance of antibodies to HIV) as HIV antigen is present in the blood before antibodies to HIV can be detected.
Composition of the panel
Test kit evaluations are carried out at the WHO Collaborating Centre in Antwerp, on the WHO HIV reference panel of well characterised serum/plasma specimens of geographically diverse origin, seroconversion panels and low titer panels. This approach allows for comparative data. In addition, field evaluations are occasionally conducted.
Other specimen types
Assessment of the performance of test kits recommended for use with other specimens types such as whole blood, oral fluid and urine, are carried out in prospective studies as these samples can not be stored. Some of these tests may be useful for VCT testing settings and hard to reach populations.
In recent years, 29 assays for the detection of HIV antibody have been evaluated, of which 19 were simple rapid tests and 5 tests were combined HIV antigen-antibody ELISAs.
HIV Assays Report 18 (HIV-1/2 antibodies rapid diagnostic tests)
HIV Assays Report 17 (HIV rapid diagnostic tests)
HIV Assays Report 16 (Rapid Tests)
HIV Assays Report 15 (Antigen/Antibody Tests)
HIV Assays Report 14 (Simple/Rapid Tests)
HIV Assays Report 13 (Urine and Saliva Tests)
HIV Assays Report 12 (Whole Blood Tests)
HIV Assays Report 11
External web sites
Request for Proposals
22 MARCH 2017
The Prequalification Team is publishing a request for proposals for consultancy services relating to - developing and maintaining the Quality Management Systems (QMS) and assuming the responsibility for on-going system maintenance and effectiveness of operations within the Prequalification Team.
The services required by the World Health Organization (WHO) are more fully described in the below attached Terms of Reference and Request for Proposals.
Proposals should be submitted to WHO in writing no later than 5 April 2017 at 17:00 hours Geneva time ("the closing date"), by email at the following address: email@example.com
- WHO list of prequalified in vitro diagnostic products
- Status of active applications to the prequalification of in vitro diagnostics
- Complaints and Product Alerts
- Streamlining of the Prequalification of Diagnostics
- WHO Prequalification of Male Circumcision Devices
- Procurement of in vitro diagnostics
- HIV incidence assay working group
- Information resources
- First WHO prequalified hepatitis C rapid test opens the door to expanded treatment
- Two cutting-edge technologies for HIV detection in infants receive WHO prequalification
- New! Alternative performance evaluation mechanism
- New! Sample product dossier for public comment
- New! Guidance for manufacturers for public comment
New! Change of WHO recommendations on malaria RDT procurement
G6PD Prequalification: Public Announcement to Stakeholders
Guidance for post-market surveillance